{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T22:59:49Z","timestamp":1786229989061,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoantibodies are important for the diagnosis of autoimmune interstitial lung disease (ILD). Standard immunoassays have limitations, including their qualitative nature and\/or a narrow dynamic range of detection, hindering the usefulness of autoantibodies as biomarkers of disease activity. Here, the luciferase immunoprecipitation system (LIPS) was evaluated for measuring myositis-specific and other lung-related autoantibodies in 25 subjects with idiopathic inflammatory myopathies (IIM), 26 with Sj\u00f6gren\u2019s disease (SjD), and 10 healthy volunteers. LIPS detected a broad dynamic range of autoantibodies, to MDA5, Jo-1, PL12, KS, U1-70K, and Ro52, and matched seropositivity status with established immunoassays. Robust anti-MDA5 autoantibodies in four IIM-ILD patients had a median value of 1,134,000 LU (IQR 473,000-2,317,000), which was 500 times higher than in 21 seronegative IIM patients. Markedly elevated anti-Jo-1 autoantibodies in five IIM-ILD patients demonstrated a median value of 1,177,000 LU (IQR: 604,000-2,520,000), which was 1000-fold higher than in seronegative patients. Robust anti-Ro52 and other anti-tRNA-synthetase autoantibodies were detected in a subset of IIM-ILD subjects. In SjD, only anti-U1-70K and KS autoantibodies were identified in ILD patients with a prevalence of 30% and 20%, respectively. In longitudinal samples of five IIM-ILD patients, anti-Jo-1 autoantibody levels paralleled clinical improvement of lung function. LIPS can accurately quantify autoantibody levels as biomarkers for treatment response in patients with autoimmune ILD.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1462242","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T04:45:18Z","timestamp":1729831518000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Quantification of autoantibodies using a luminescent profiling method in autoimmune interstitial lung disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Peter D.","family":"Burbelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Huapaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Khavandgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Pinal-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Chiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Noroozi Farhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Schiffenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakali","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake M.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1759720X211037519","DOI":"10.1177\/1759720X211037519","article-title":"Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders","volume":"13","author":"Panagopoulos","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866087","article-title":"Aminoacyl-tRNA synthetases: on anti-synthetase syndrome and beyond","volume":"13","author":"Galindo-Feria","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151067","article-title":"Pulmonary involvement in the antisynthetase syndrome: A comparative cross-sectional study","volume":"43","author":"Andersson","year":"2016","journal-title":"J Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road011","article-title":"New aspects of clinical and immunological characteristics in patients with anti-asparaginyl tRNA synthetase (anti-KS) autoantibody","volume":"34","author":"Hosono","year":"2023","journal-title":"Mod Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101767","DOI":"10.1016\/j.berh.2022.101767","article-title":"Autoantibodies: pathogenic or epiphenomenon","volume":"36","author":"Galindo-Feria","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000957","article-title":"Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies","volume":"35","author":"Choi","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223873","article-title":"Transcriptional derepression of CHD4\/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v38.i4","article-title":"Immunopathogenesis of the anti-synthetase syndrome","volume":"38","author":"Gayed","year":"2018","journal-title":"Crit Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/s14zq8","article-title":"Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank","volume":"42","author":"Loganathan","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2014.08.006","article-title":"Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases","volume":"165","author":"Burbelo","year":"2015","journal-title":"Transl Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032001","article-title":"Two major autoantibody clusters in systemic lupus erythematosus","volume":"7","author":"Ching","year":"2012","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/08916930902911738","article-title":"Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren\u2019s syndrome","volume":"42","author":"Burbelo","year":"2009","journal-title":"Autoimmunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1479-5876-7-83","article-title":"Rapid serological detection of autoantibodies associated with Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Burbelo","year":"2009","journal-title":"J Trans Med"},{"key":"B22","article-title":"Extraordinary antigenicity of the human Ro52 autoantigen","volume":"2","author":"Burbelo","year":"2010","journal-title":"Am J Transl Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing","year":"2020","journal-title":"Respir Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002015","article-title":"Clinical characteristics and prognostic value of ro52\/SSA antibodies in idiopathic inflammatory myopathies","volume":"29","author":"Pepper","year":"2023","journal-title":"J Clin Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab488","article-title":"Myositis specific antibodies are associated with isolated anti-Ro-52 associated interstitial lung disease","volume":"61","author":"Shao","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220139","article-title":"Coexistence of anti-ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk","volume":"50","author":"Lv","year":"2023","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5597","article-title":"Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance","volume":"11","author":"Ferre","year":"2019","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1038\/s41598-018-21522-7","article-title":"Autoantibodies against the Immunoglobulin-Binding Region of Ro52 Link its Autoantigenicity with Pathogen Neutralization","volume":"8","author":"Burbelo","year":"2018","journal-title":"Sci Rep"},{"key":"B33","article-title":"Antibody profiling by luciferase immunoprecipitation systems (LIPS)","volume":"32","author":"Burbelo","year":"2009","journal-title":"J Vis Exp"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.08.23289640","article-title":"Antigenic responses are hallmarks of fibrotic interstitial lung diseases independent of underlying etiologies","author":"Yoon","year":"2023","journal-title":"medRxiv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11696","article-title":"Phage immunoprecipitation-sequencing reveals CDHR5 autoantibodies in select patients with interstitial lung disease","author":"Upadhyay","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.39497","article-title":"Brief report: patients with primary Sjogren\u2019s syndrome who are positive for autoantibodies to tripartite motif-containing protein 38 show greater disease severity","volume":"68","author":"Wolska","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102951","DOI":"10.1016\/j.jaut.2022.102951","article-title":"Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies","volume":"134","author":"Preger","year":"2023","journal-title":"J Autoimmun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01327","article-title":"Pulmonary manifestations of primary Sjogren\u2019s syndrome: underlying immunological mechanisms, clinical presentation, and management","volume":"10","author":"Gupta","year":"2019","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/ar1490","article-title":"Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease","volume":"7","author":"Hof","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.resinv.2019.12.003","article-title":"Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease","volume":"58","author":"Aiko","year":"2020","journal-title":"Respir Investig"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222686","article-title":"Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies","volume":"82","author":"Vulsteke","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220514","article-title":"Autoantibodies against type I IFNs in patients with critical influenza pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J Exp Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005112022","article-title":"Prediagnostic appearance of thrombospondin type-1 domain 7A autoantibodies in membranous nephropathy","volume":"4","author":"Burbelo","year":"2023","journal-title":"Kidney360"},{"key":"B46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13075-022-02745-6","article-title":"Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome","volume":"24","author":"Notarnicola","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew470","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1134\/S1607672923700266","article-title":"Anti-topoisomerase 1 antibody level changes after B cell depletion therapy in systemic sclerosis","volume":"511","author":"Ananyeva","year":"2023","journal-title":"Dokl Biochem Biophys"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.41403","article-title":"Association of anti-topoisomerase I antibodies of the igM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1462242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T04:45:21Z","timestamp":1729831521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1462242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2024.1462242"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1462242","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"article-number":"1462242"}}